Given that PARPis can slow AML cell growth and affect the differentiation of AML1-ETO- and PML-RARA-transformed mouse cells, we postulated that olaparib may repress CML progression in vivo. The gene discussed is RUNX1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.